Asian Activities Report for October 10, 2011: Carabella Resources (ASX:CLR) Appoints New Managing Director to Strengthen Expertise in the Coal Industry
Sydney, Oct 10, 2011 AEST (ABN Newswire) - Carabella Resources Limited (ASX:CLR) announced the appointment of experienced coal industry executive Anthony Quin as Managing Director to strengthen the Company's coal expertise at Board level. Anthony is a prominent member of the Queensland coal industry, having served 14 years with BHP Billiton (ASX:BHP) including two years as Chief Development Officer of its Metallurgical Coal business, the world's largest exporter of metallurgical coal. This appointment is in line with Carabella's continuous commitment to the development of the Grosvenor West coking and thermal coal deposits and the broader Mabbin Creek coal area.
Tasman Resources Limited (ASX:TAS) has signed a conditional agreement with Rio Tinto Limited (ASX:RIO) for the funding of an accelerated exploration program on Tasman's Vulcan prospect. The Agreement will see an immediate cash injection of A$10 million into Tasman for this highly prospective iron-oxide copper gold uranium prospect, located 30 kilometres from BHP Billiton's giant Olympic Dam copper-gold-uranium mine in South Australia.
Acer Energy Limited (ASX:ACN) has executed a conditional Sale and Purchase Agreement with Sundance Energy Australia Limited (ASX:SEA) to acquire all of Sundance's 23.33% working interest in Petroleum Exploration Licence 100 in Cooper Basin, South Australia. The Licence is immediately east of the Acer Energy's PEL 182 block and directly west of the Telopea and Keleary oil fields which have produced in excess of 2 million barrels of oil.
Starpharma Holdings Limited (ASX:SPL) has received agreement from the US Food and Drug Administration regarding the Phase 3 clinical trial program for the Company's VivaGel (R) bacterial vaginosis treatment. The Phase 3 clinical trial follows a successful Phase 2 study which proved significant efficacy for treatment of bacterial vaginosis, and will be the final phase of the development of VivaGel (R) before the Company seeks commercialisation of the treatment.